EHA 2021 | PACIFICA: pacritinib versus physician’s choice in myelofibrosis
John Mascarenhas, MD, Mount Sinai, New York, NY, gives an overview of an ongoing Phase III PACIFICA study (NCT03165734) of pacritinib in patients with primary myelofibrosis, port-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis who are ruxolitinib-naïve. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
PACIFICA study is a registration randomized Phase III study of patients with higher-risk myelofibrosis that are ruxolitinib treatment naïve, or at least have less than 90 days of prior JAK inhibitor therapy, with a baseline platelet count of less than 50,000.
This study randomizes patients to best available therapy, which is predetermined by the investigator, and can include low dose ruxolitinib, hydroxyurea, danazol, or prednisone, to pacritinib 200 milligrams twice daily...
PACIFICA study is a registration randomized Phase III study of patients with higher-risk myelofibrosis that are ruxolitinib treatment naïve, or at least have less than 90 days of prior JAK inhibitor therapy, with a baseline platelet count of less than 50,000.
This study randomizes patients to best available therapy, which is predetermined by the investigator, and can include low dose ruxolitinib, hydroxyurea, danazol, or prednisone, to pacritinib 200 milligrams twice daily. The primary endpoint is SVR 35% at 24 weeks. And a key secondary endpoint is total symptom score reduction. This is an important study to establish the benefit of pacritinib in this population with extreme thrombocytopenia, which represents an urgent unmet need. And this trial is ongoing.
Read more...
Disclosures
John Mascarenhas, MD, has received institutional research support from Incyte, Novartis, Merck, Kartos, PharmaEssentia, Forbius, Roche and CTI BIO; and has received consultancy fees from Incyte, BMS, Roche, Sierra Oncology, PharmaEssentia, CTI bio, Constellation and Kartos.
